Spectrophotometric Methods for Determination of Sunitinib in Pharmaceutical Dosage Forms Based on Ion-pair Complex Formation

Overview

Journal Iran J Pharm Res

Publisher Brieflands

Specialty Pharmacology

Date 2021 Mar 8

PMID 33680014

Citations 4

Authors

Effat Souri

Eynollah Amoon

Nazanin Shabani Ravari

Fereshteh Keyghobadi

Maliheh Barazandeh Tehrani

Affiliations

Soon will be listed here.

Abstract

Three rapid spectrophotometric methods were developed for the determination of sunitinib based on the formation of ion-pair complex in acidic medium with bromocresol purple, bromothymol blue, and bromophenol blue. The formed ion-pair complexes, extractable with chloroform, were measured at 422 nm for bromocresol purple, 425 nm for bromothymol blue and 427 nm for bromophenol blue. All these methods were optimized for the pH of buffer and the volume of the reagent. The methods were linear over the range of 1-200 µg/mL for bromocresol purple, 1-150 µg/mL for bromothymol blue, and 2-200 µg/mL for bromophenol blue with a very low limit of quantification and acceptable accuracy and precision. Using the proposed methods for determination of sunitinib in pharmaceutical dosage forms showed reliable results comparable to previously published method.

Citing Articles

Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring.

Chen L, Zhang Y, Zhang Y, Wang W, Sun D, Li P J Pharm Anal. 2024; 14(4):100899.

PMID: 38634061 PMC: 11022103. DOI: 10.1016/j.jpha.2023.11.006.

Development of Green and High Throughput Microplate Reader-Assisted Universal Microwell Spectrophotometric Assay for Direct Determination of Tyrosine Kinase Inhibitors in Their Pharmaceutical Formulations Irrespective the Diversity of Their Chemical....

Darwish I, Alzoman N Molecules. 2023; 28(10).

PMID: 37241790 PMC: 10223063. DOI: 10.3390/molecules28104049.

Spectrophotometric Investigations of Charge Transfer Complexes of Tyrosine Kinase Inhibitors with Iodine as a σ-Electron Acceptor: Application to Development of Universal High-Throughput Microwell Assay for Their Determination in Pharmaceutical....

Darwish I, Darwish H, Ali A, Almutairi H Medicina (Kaunas). 2023; 59(4).

PMID: 37109733 PMC: 10143458. DOI: 10.3390/medicina59040775.

Experimental and Computational Evaluation of Chloranilic Acid as an Universal Chromogenic Reagent for the Development of a Novel 96-Microwell Spectrophotometric Assay for Tyrosine Kinase Inhibitors.

Darwish I, Darwish H, Khalil N, Sayed A Molecules. 2021; 26(3).

PMID: 33572664 PMC: 7866968. DOI: 10.3390/molecules26030744.

References

Fabian M, Biggs 3rd W, Treiber D, Atteridge C, Azimioara M, Benedetti M . A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005; 23(3):329-36. DOI: 10.1038/nbt1068. View

Faivre S, Demetri G, Sargent W, Raymond E . Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007; 6(9):734-45. DOI: 10.1038/nrd2380. View

Minkin P, Zhao M, Chen Z, Ouwerkerk J, Gelderblom H, Baker S . Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 874(1-2):84-8. PMC: 2612784. DOI: 10.1016/j.jchromb.2008.09.007. View

Abrams T, Lee L, Murray L, Pryer N, Cherrington J . SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2(5):471-8. View

Honeywell R, Yarzadah K, Giovannetti E, Losekoot N, Smit E, Walraven M . Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878(15-16):1059-68. DOI: 10.1016/j.jchromb.2010.03.010. View

Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann O, Ofarrell A . A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2004; 105(3):986-93. DOI: 10.1182/blood-2004-05-1846. View

Rini B . Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res. 2007; 13(4):1098-106. DOI: 10.1158/1078-0432.CCR-06-1989. View

Blanchet B, Saboureau C, Benichou A, Billemont B, Taieb F, Ropert S . Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta. 2009; 404(2):134-9. DOI: 10.1016/j.cca.2009.03.042. View

Lankheet N, Hillebrand M, Rosing H, Schellens J, Beijnen J, Huitema A . Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr. 2012; 27(4):466-76. DOI: 10.1002/bmc.2814. View

10.

Bello C, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J . Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs. 2006; 17(3):353-8. DOI: 10.1097/00001813-200603000-00015. View

11.

Atkins M, Jones C, Kirkpatrick P . Sunitinib maleate. Nat Rev Drug Discov. 2006; 5(4):279-80. DOI: 10.1038/nrd2012. View

12.

Etienne-Grimaldi M, Renee N, Izzedine H, Milano G . A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877(29):3757-61. DOI: 10.1016/j.jchromb.2009.09.011. View

13.

Chow L, Eckhardt S . Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007; 25(7):884-96. DOI: 10.1200/JCO.2006.06.3602. View

14.

de Bruijn P, Sleijfer S, Lam M, Mathijssen R, Wiemer E, Loos W . Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 2009; 51(4):934-41. DOI: 10.1016/j.jpba.2009.10.020. View

15.

Qiu F, Bian W, Li J, Ge Z . Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2012; 27(5):615-21. DOI: 10.1002/bmc.2836. View

16.

Britten C, Kabbinavar F, Hecht J, Bello C, Li J, Baum C . A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2007; 61(3):515-24. DOI: 10.1007/s00280-007-0498-4. View

17.

Adams V, Leggas M . Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther. 2007; 29(7):1338-53. DOI: 10.1016/j.clinthera.2007.07.022. View